Effect of Modulen vs budesonide on clinical response and mucosal healing in Crohn’s patients

doi:10.3748/wjg.v31.i5.100238

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1061)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-5) series.

Item

Count

PDF

HTML

581

Tables (1-5)

Sum=669

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

163

Sum=250

Publishing Process of This Article

Item

Count

Browse

Download

Sum=92

Feb 7, 2025 (publication date) through Feb 5, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Feb 7, 2025; 31(5): 100238
Published online Feb 7, 2025. doi: 10.3748/wjg.v31.i5.100238

Table 4 Intention for treat analysis in the budesonide group (9 patients), mean ± SD

	Baseline	End of I month of treatment	End of II months of treatment	Follow-up	P value
Weight (kg)	82.9 ± 17.3	80.8 ± 18.3	78.5 ± 14.6	75.8 ± 15.6	0.81¹; 0.69²; 0.47³
CDAI	191.4 ± 60.6	113.6 ± 75.3	152.4 ± 75.9	103.6 ± 83.1	0.042¹; 0.35²; 0.063³
IBDQ	149.3 ± 35.8	173.9 ± 30.4	164.4 ± 29.1	173.7 ± 27.8	0.15¹; 0.38²; 0.15³
Lewis score (median with IQR)	412 (337-1379)	NA	337 (0-1690)	NA	0.56
Total inflammatory score (median with IQR)	637 (476-1264)	NA	674 (0-809)	NA	0.75
I tertile (median with IQR)	143 (67.5-393.5)	NA	135 (0-337)	NA	0.59
II tertile (median with IQR)	0 (0-236)	NA	0 (0-337)	NA	1.00
III tertile (median with IQR)	337 (240-574)	NA	337 (0-412)	NA	0.79
Total symptom score	3.72 ± 1.83	2.45 ± 1.59	3.21 ± 2.48	2.96 ± 2.22	0.22¹; 0.65²; 0.45³
Calprotectin (μg/mg) (median with IQR)	336 (84-697)	77.7 (15-358)	14 (8.7-46.65)	15 (13.4-61)	0.022¹; 0.008²; 0.013³
Hemoglobin (g/dL)	13.4 ± 1.28	14.03 ± 1.67	13.87 ± 1.89	13.99 ± 1.64	0.38¹; 0.54²; 0.45³
CRP (median with IQR)	3.6 (1.15-15.6)	1.2 (0.53-2.77)	1.0 (0.5-3.0)	1.0 (0.5-2)	0.08¹; 0.10²; 0.20³

¹P baseline vs end of I month of treatment.

²P baseline vs end of II months of treatment.

³P baseline vs end of follow up of treatment.

IQR: Interquartile range; NA: Not applicable; CDAI: Crohn’s disease activity index; IBDQ: Inflammatory bowel disease questionnaire; CRP: C-reactive protein.

Citation: Ovadia B, Niv E, Stern Katie S, Mahajna E, Gal O, Kopelman Y. Effect of Modulen vs budesonide on clinical response and mucosal healing in Crohn’s patients. World J Gastroenterol 2025; 31(5): 100238
URL: https://www.wjgnet.com/1007-9327/full/v31/i5/100238.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i5.100238